Literature DB >> 27648372

PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo.

Aishwarya Vijay1, Shuo Wang2, Patrick Worhunsky1, Ming-Qiang Zheng1, Nabeel Nabulsi1, Jim Ropchan1, Suchitra Krishnan-Sarin3, Yiyun Huang1, Evan D Morris4.   

Abstract

Opioid receptors may play critical roles in alcoholism and other addictions, addiction withdrawal, and depression and are considered pharmacological targets for treatment of these conditions. Sex differences have been demonstrated in mu (MOR) and delta (DOR) opioid receptors in humans, in vivo. In addition, sex differences have been observed in efficacy of treatment targeting kappa opioid receptors (KOR). Our goal in the present study was to compare the availability of KOR (1) between healthy control (HC) men and women. Twenty-seven subjects-18 males (M) and 9 females (F)-underwent PET scans with [(11)C] LY2795050, a selective kappa antagonist tracer. Partial volume correction was applied to all PET data. Volume of distribution (V T) of the tracer was estimated regionally as well as at the voxel level. V T values of males versus females were compared for 19 defined ROIs. Results at the regional and voxel levels were consistent. Males had significantly higher V T and thus a higher KOR availability than women in multiple brain regions. To our knowledge, this is the first report of sex differences in the KOR system in humans, in vivo. These findings could have implications for the treatment of pain with kappa opioid analgesics. The results may also have an impact on the diagnosis and treatment of addictive and other disorders.

Entities:  

Keywords:  PET imaging; Sex differences; kappa opioid receptor system; volume of distribution

Year:  2016        PMID: 27648372      PMCID: PMC5004062     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  36 in total

1.  Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.

Authors:  Shelly F Greenfield; Helen M Pettinati; Stephanie O'Malley; Patrick K Randall; Carrie L Randall
Journal:  Alcohol Clin Exp Res       Date:  2010-07-20       Impact factor: 3.455

Review 2.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

3.  Multi-modal volume registration by maximization of mutual information.

Authors:  W M Wells; P Viola; H Atsumi; S Nakajima; R Kikinis
Journal:  Med Image Anal       Date:  1996-03       Impact factor: 8.545

4.  Cluster-extent based thresholding in fMRI analyses: pitfalls and recommendations.

Authors:  Choong-Wan Woo; Anjali Krishnan; Tor D Wager
Journal:  Neuroimage       Date:  2014-01-08       Impact factor: 6.556

5.  Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving.

Authors:  J K Zubieta; D A Gorelick; R Stauffer; H T Ravert; R F Dannals; J J Frost
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

Review 6.  Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.

Authors:  Brendan M Walker; Glenn R Valdez; Jay P McLaughlin; Georgy Bakalkin
Journal:  Alcohol       Date:  2012-03-27       Impact factor: 2.405

7.  Test-retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the κ opioid receptor.

Authors:  Mika Naganawa; Ming-Qiang Zheng; Shannan Henry; Nabeel Nabulsi; Shu-Fei Lin; Jim Ropchan; David Labaree; Soheila Najafzadeh; Michael Kapinos; Johannes Tauscher; Alexander Neumeister; Richard E Carson; Yiyun Huang
Journal:  J Nucl Med       Date:  2015-01-15       Impact factor: 10.057

Review 8.  Sex differences in opioid analgesia: "from mouse to man".

Authors:  Rebecca M Craft
Journal:  Clin J Pain       Date:  2003 May-Jun       Impact factor: 3.442

Review 9.  Sex differences in kappa opioid pharmacology.

Authors:  Khampaseuth Rasakham; Lee-Yuan Liu-Chen
Journal:  Life Sci       Date:  2010-10-14       Impact factor: 5.037

10.  Differential effects of bremazocine on oral phencyclidine (PCP) self-administration in male and female rhesus monkeys.

Authors:  Kelly P Cosgrove; Marilyn E Carroll
Journal:  Exp Clin Psychopharmacol       Date:  2004-05       Impact factor: 3.157

View more
  26 in total

1.  The kappa opioid receptor modulates GABA neuron excitability and synaptic transmission in midbrainprojections from the insular cortex.

Authors:  Melanie M Pina; Dipanwita Pati; Lara S Hwa; Sarah Y Wu; Alexandra A Mahoney; Chiazam G Omenyi; Montserrat Navarro; Thomas L Kash
Journal:  Neuropharmacology       Date:  2019-12-21       Impact factor: 5.250

Review 2.  Opioid use disorder.

Authors:  John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh
Journal:  Nat Rev Dis Primers       Date:  2020-01-09       Impact factor: 52.329

3.  Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection.

Authors:  Louise Geddes; Jenny Iversen; Handan Wand; Aryan Esmaeili; Judith Tsui; Margaret Hellard; Gregory Dore; Jason Grebely; Paul Dietze; Julie Bruneau; Maria Prins; Megan D Morris; Naglaa H Shoukry; Andrew R Lloyd; Arthur Y Kim; Georg Lauer; Andrea L Cox; Kimberly Page; Lisa Maher
Journal:  Clin Infect Dis       Date:  2020-01-01       Impact factor: 9.079

4.  Kappa Opioid Receptors Drive a Tonic Aversive Component of Chronic Pain.

Authors:  Shiwei Steve Liu; Sarah Pickens; Nicole E Burma; Ines Ibarra-Lecue; Hongyan Yang; Lihua Xue; Chris Cook; Joshua K Hakimian; Amie L Severino; Lindsay Lueptow; Kristina Komarek; Anna M W Taylor; Mary C Olmstead; F Ivy Carroll; Caroline E Bass; Anne M Andrews; Wendy Walwyn; Tuan Trang; Christopher J Evans; Frances M Leslie; Catherine M Cahill
Journal:  J Neurosci       Date:  2019-03-12       Impact factor: 6.167

Review 5.  Opioid system and human emotions.

Authors:  Lauri Nummenmaa; Lauri Tuominen
Journal:  Br J Pharmacol       Date:  2017-05-24       Impact factor: 8.739

6.  Nociceptin Receptors Upregulated in Cocaine Use Disorder: A Positron Emission Tomography Imaging Study Using [11C]NOP-1A.

Authors:  Rajesh Narendran; Savannah Tollefson; Michael L Himes; Jennifer Paris; Brian Lopresti; Roberto Ciccocioppo; N Scott Mason
Journal:  Am J Psychiatry       Date:  2019-05-06       Impact factor: 18.112

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

Review 8.  Dynorphin and its role in alcohol use disorder.

Authors:  Anushree N Karkhanis; Ream Al-Hasani
Journal:  Brain Res       Date:  2020-02-28       Impact factor: 3.252

Review 9.  Sex/gender differences in brain function and structure in alcohol use: A narrative review of neuroimaging findings over the last 10 years.

Authors:  Terril L Verplaetse; Kelly P Cosgrove; Jody Tanabe; Sherry A McKee
Journal:  J Neurosci Res       Date:  2020-04-24       Impact factor: 4.164

10.  Kappa opioid receptor binding in major depression: A pilot study.

Authors:  Jeffrey M Miller; Francesca Zanderigo; Priya D Purushothaman; Christine DeLorenzo; Harry Rubin-Falcone; R Todd Ogden; John Keilp; Maria A Oquendo; Nabeel Nabulsi; Yiyun H Huang; Ramin V Parsey; Richard E Carson; J John Mann
Journal:  Synapse       Date:  2018-07-17       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.